Sinovac Biotech set to climb after firm is selected to supply seasonal influenza vaccine in China Print E-mail
By Staff and Wire Reports   
Thursday, 13 October 2011 07:08

FDA CalendarSinovac Biotech Ltd. (Nasdaq:SVA) announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the four manufacturers to supply seasonal influenza vaccine to the citizens of Beijing for the fourth time.

 

Dr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "We are pleased to be chosen as one of the suppliers by the Beijing CDC for the seasonal flu vaccine campaign for the year of 2011. After the comprehensive evaluation of several different factors including product quality, service and price, Sinovac was selected for the fourth time, which further validates the high quality of our flu vaccine and our commitment to service as recognized by CDC customers. We look forward to working closely with the Beijing CDC to deliver our Anflu vaccine to the citizens under the vaccination campaign."

Starting in 2007, to prevent and control the seasonal flu, the Beijing CDC began purchasing the seasonal flu vaccines to immunize the elderly over 60 and the elementary and secondary school students in Beijing.

In 2011, the Beijing CDC plans to order a total of two million doses for this vaccination campaign. The total quantity to be supplied will depend on the actual demand in Beijing. In 2010, total about 269,000 doses of Anflu were inoculated to the target population for the vaccination campaign in Beijing. According to the Beijing Health Bureau's data as of November 30, 2010, approximately 1.6 million Beijing citizens were inoculated with the seasonal flu vaccines, inclusive of the target population covered by the free vaccination campaign.

Sinovac's research and development is focused on two aspects: 1) Original vaccines for new infectious diseases such as SARS and Avian Influenza; and 2) Technological renovation of traditional vaccine such as Japanese Encephalitis. Its R&D pipeline includes: EV71 vaccine, Pneumococcal Conjugate vaccine, HIB vaccine, Meningitis vaccine, Japanese Encephalitis vaccine, Rabies vaccine, etc. The company's product portfolio includes: Healive, an inactivated hepatitis A vaccine; Bilive®, an inactivated hepatitis A and B vaccine; Anflu, a split influenza vaccine; Panflu®, an inactivated H5N1 influenza (avian flu) vaccine; etc. 

Shares of  
Sinovac are trading just under their 50-day moving average at -56% from their 52-Wk High ($ 5.06 ). They closed the previous session at $2.22.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter